Pharma Legal, Enforcement & Alert Intelligence

B. Sanjay Kumar v. State of Tamil Nadu

Decision focus: Licensing, storage, medical-use or distribution controls for medicines and regulated substances.

Dr. D. Bhaskara Rao v. State of Telangana

Decision focus: Licensing, storage, medical-use or distribution controls for medicines and regulated substances.

Shailyamanyu Singh v. State of Maharashtra

Decision focus: Personal liability of directors, partners or company officers under the Drugs and Cosmetics Act.

Anav Jain v. State of Haryana

Decision focus: Licensing, storage, medical-use or distribution controls for medicines and regulated substances.

Nirma Limited through Ajay Bhushanlal Nanavati v. State of Gujarat

Decision focus: Drug-quality testing, NSQ classification, retesting rights, shelf life or prosecution timing.

Lalankumar Singh & Others v. State of Maharashtra

Decision focus: Personal liability of directors, partners or company officers under the Drugs and Cosmetics Act.

M/s Celebrity Biopharma Limited & Others v. Union of India

Decision focus: NSQ and misbranding prosecution, sampling safeguards and mandatory inquiry before issuing process.

M/s Carenow Medical Pvt. Ltd. v. Drugs Inspector

Decision focus: Drug-quality testing, NSQ classification, retesting rights, shelf life or prosecution timing.

M/s Zest Pharma & Others v. State represented by the Drugs Inspector

Decision focus: Drug-quality testing, NSQ classification, retesting rights, shelf life or prosecution timing.

Union of India v. Ashok Kumar Sharma & Others

Decision focus: Authority of police and Drug Inspectors to investigate and institute prosecutions for Chapter IV drug-law offences.

Applicant v. State of Uttarakhand

Decision focus: Competence of the criminal court after designation of a Special Court for specified drug offences.

M/s Laborate Pharmaceuticals India Ltd. v. State of Jammu & Kashmir & Others

Decision focus: Prosecution delay, shelf-life expiry and loss of the manufacturer’s statutory reanalysis opportunity.

Union of India & Another v. Pfizer Limited & Others

Decision focus: Regulatory decision-making and expert review for prohibition notifications issued under Section 26A.

Laborate Pharmaceuticals India Limited & Others v. State of Tamil Nadu

Decision focus: Loss of Central Laboratory reanalysis rights because the sample portion and cognizance were delayed beyond shelf life.

Laborate Pharmaceuticals India Ltd. & Others v. State represented by the Drugs Inspector

Decision focus: Substandard-drug prosecution, timing of reanalysis and asserted responsibility of company directors.

Zee Laboratory v. Union of India

Summary: The Punjab and Haryana High Court classified an NSQ Cefpodoxime dissolution failure and examined whether the complaint filed more than three years later was time-barred.

Outcome / action: The Court quashed the delayed complaint, summoning order and consequential proceedings, holding that an NSQ dissolution failure without the required spurious or serious-harm allegations attracted Section 27(d) and the corresponding limitation period.

Practical impact: The analyst finding and complaint must support the exact Section 27 category; limitation should be calculated from the legally sustainable offence rather than a more serious unsupported charge.

Sanjeev Kumar Bhatia & Others v. Union of India

Summary: The Gauhati High Court reviewed an NSQ Primaquine prosecution, a cognizance order citing a non-existent provision and differing responsibility of directors and technical personnel.

Outcome / action: The complaint was quashed against six directors for want of specific Section 34 allegations; the defective cognizance order was set aside in full and the complaint against technical personnel and the company was remitted for fresh judicial consideration.

Practical impact: Cognizance must identify an existing offence and show application of mind; complaints must distinguish general directors from specifically responsible manufacturing and testing personnel.

Pharmaceutical Firm Partners v. Union of India

Summary: The Himachal Pradesh High Court examined personal responsibility of firm partners in a prosecution involving alleged NSQ manufacture, stocking and statutory-document contraventions.

Outcome / action: The petition was allowed and the complaint, cognizance order and consequential proceedings were quashed against the petitioners, who were discharged from the NSQ and licensing prosecution.

Practical impact: Prosecution material should connect each partner with the relevant conduct and responsibility rather than relying on partnership status alone.

M/s Unison Pharmaceuticals & Others v. Union of India

Summary: The Himachal Pradesh High Court reviewed an NSQ prosecution concerning Rabeprazole and Domperidone sustained-release capsules and responsibility of firm partners.

Outcome / action: The petition was allowed and the complaint and consequential proceedings were quashed against the petitioners because the record did not connect the partners with day-to-day responsibility and the process order lacked adequate application of mind.

Practical impact: Complaints and summoning orders should identify the factual basis for each partner’s responsibility and record sufficient reasons for issuing process.

Anshul Agarwal & Others v. State of Uttar Pradesh

Summary: The Allahabad High Court considered proceedings concerning a veterinary bolus reported to contain no ivermectin and to carry inconsistent labelling.

Outcome / action: The application was dismissed; company-officer responsibility, joinder of the company and disputed facts concerning a spurious and misbranded veterinary drug were left for the trial court.

Practical impact: At the initial stage, disputed director responsibility and company joinder may not justify quashing; testing and labelling records should support the role attributed to every accused.

Smt. Meena Pandey & Others v. State of Uttar Pradesh

Summary: The Allahabad High Court reviewed a retail-drug prosecution involving an analyst finding that the sample contained neither declared active ingredient.

Outcome / action: The quashing application was rejected because the analyst report alleged a spurious product and objections to sampling and evidentiary responsibility required adjudication at trial.

Practical impact: Sampling disputes and factual defences ordinarily require trial where the complaint and analyst report disclose a prima facie spurious-drug case.

Varghese Paul v. Regional Drug Inspector

Summary: The Kerala High Court reviewed conviction relating to Magnesium Sulphate paste and the evidentiary value of CDL testing conducted after expiry.

Outcome / action: The revision was allowed, the concurrent conviction was set aside and the accused was acquitted because official delay caused Central Drugs Laboratory testing only after shelf-life expiry, defeating the Section 25(4) safeguard.

Practical impact: Government analysis, complaint filing and court-directed CDL testing must occur while the sample remains capable of meaningful analysis.

C. B. Healthcare & Others v. Union of India through Drug Inspector

Summary: The Bombay High Court considered delayed sampling and prosecution, shelf-life expiry, retesting rights and allegations against company directors.

Outcome / action: The writ petition was allowed and the process order and criminal complaint were quashed because prosecution delay defeated the Section 25 retesting safeguard and continuation would abuse the process of court.

Practical impact: Complete analysis, retesting and prosecution steps within shelf life, and plead each officer’s actual responsibility rather than statutory wording alone.

Chemwel Pharma Ltd. v. State of Kerala

Summary: The Kerala High Court considered marketer liability for an Amoxycillin dry-syrup label showing a shelf life longer than Schedule P permitted.

Outcome / action: The petition was allowed and proceedings were quashed against the marketer and its managing director because the alleged 2013 misbranding preceded Rule 84E and the complaint lacked clear mens rea allegations against them.

Practical impact: For conduct before Rule 84E, marketer liability cannot be assumed from marketing status alone; allegations should identify the applicable provision and culpable conduct.

M/s Landmark Hospitals v. State of Telangana

Summary: The Telangana High Court reviewed prosecution over medicines temporarily stocked in a hospital cellar outside the specifically licensed pharmacy area.

Outcome / action: The petition was allowed and proceedings were quashed because the hospital held a valid licence, no sale from the cellar was shown and temporary stocking alone did not establish the alleged unlicensed-sale offence.

Practical impact: Hospitals should align all storage areas with licence particulars and inventory controls; enforcement should distinguish storage for internal use from evidence of an unlicensed sale.

M/s SBS Biotech & Others v. State of Himachal Pradesh

Summary: The Supreme Court dismissed the appeal concerning prosecution for alleged failure to maintain and furnish manufacturing records and upheld committal of the case to the Court of Sessions.

Outcome / action: Appeal dismissed; the Supreme Court found no error in the High Court decision and upheld committal of the case to the Court of Sessions.

Practical impact: Manufacturers should maintain and produce the records required by the Act, Rule 74 and Schedules M and U. The judgment also discusses which court may try Chapter IV offences.

State of Chhattisgarh v. M/s Paras Pharmaceutical Product & Others

Summary: The Chhattisgarh High Court reviewed an NSQ Paraquin-tablet prosecution involving a retailer, wholesalers, manufacturer and partners.

Outcome / action: The State’s acquittal appeal was dismissed because the prosecution failed to prove the complete distribution chain with primary records and expiry deprived the manufacturer of meaningful Central Drugs Laboratory reanalysis.

Practical impact: Prosecutors should prove the supply chain with original invoices and preserve effective Section 25 retesting before shelf-life expiry.

M/s Omega Pharma v. State of Madhya Pradesh & Others

Summary: The Madhya Pradesh High Court considered delayed testing, broken Diclofenac-Paracetamol tablets, retesting procedure and blacklisting under a public procurement contract.

Outcome / action: The petitions challenging NSQ findings, recovery and two-year product blacklisting were dismissed with liberty to use the contractual appeal and dispute-resolution remedies.

Practical impact: Suppliers should exhaust tender appeals promptly and document custody, testing timelines and contractual second-sample rights when contesting NSQ sanctions.

M/s Agron Remedies Pvt. Ltd. & Others v. State of Maharashtra

Summary: The Bombay High Court reviewed the timing of the analyst report, retesting request, sanction and complaint in relation to expiry of Atorvastatin tablets.

Outcome / action: The petition was allowed and the complaint, proceedings and process order were quashed because the complaint followed shelf-life expiry, the statutory retesting right was lost and sanction preceded consideration of the manufacturer’s response.

Practical impact: Enforcement timelines should allow meaningful CDL retesting, and sanctioning authorities should consider the manufacturer’s response before deciding prosecution.

M/s Jackson Laboratory Pvt. Ltd. & Another v. State of Himachal Pradesh

Summary: The Himachal Pradesh High Court considered alleged fake-labelled spurious capsules, loss of retesting opportunity, delayed analysis and the Magistrate-to-Sessions committal procedure.

Outcome / action: The quashing petition was dismissed; the complaint could continue on alleged spurious manufacture even without relying on the analyst report, and committal through the Magistrate to the Sessions Court was held proper.

Practical impact: Spurious status may arise from false manufacturer identity or substitution independently of chemical analysis; complaints for Chapter IV offences still follow statutory committal procedure.

M/s Gautam Gambhir Foundation & Others v. State of NCT of Delhi

Summary: The Delhi High Court considered charitable procurement and free distribution of Favipiravir during the COVID-19 emergency under medical supervision.

Outcome / action: The petition was allowed and the complaint and summoning orders were quashed; the Court found compliant procurement and medically supervised charitable distribution during COVID-19 and held that continuing prosecution would abuse process.

Practical impact: Emergency aid providers should procure from licensed sources, maintain invoices, patient and medical-supervision records, and document compliant storage and distribution.

Smt. Seema Chandrashekar & Another v. State of Karnataka

Summary: The Karnataka High Court considered retailer liability arising from hand-sanitizer products manufactured by another firm.

Outcome / action: The petition was allowed and the proceedings were quashed against the medical-store petitioners because the material did not establish knowing storage or sale of an unlicensed or NSQ product and the statutory defence was relevant.

Practical impact: Licensed retailers should retain purchase, supplier-licence and storage records supporting due diligence and the Section 19 defence.

M/s Theon Pharmaceuticals Limited & Others v. State of Kerala

Summary: The Kerala High Court considered a renewed challenge to prosecution involving an allegedly false reconstitution ring on C-Furo Dry Syrup packaging.

Outcome / action: The petition was dismissed because substantially similar quashing grounds had already been rejected in an earlier proceeding and the Supreme Court had dismissed the related special leave petition.

Practical impact: A later quashing petition cannot ordinarily re-open substantially identical grounds already decided; individual-role objections should be raised fully at the first opportunity.

M/s Hetero Drug Ltd. & Others v. State represented by Drugs Inspector

Summary: The Madras High Court reviewed a long-pending prosecution against manufacturers and distributors concerning labelling, alleged misbranding and sale-licence conditions.

Outcome / action: The petitions were allowed and the entire complaint was quashed because the Court found no substance capable of sustaining the misbranding, labelling and licensing prosecution concerning Enthusia-50 tablets.

Practical impact: Complaints should identify a sustainable statutory breach for each manufacturer, marketer and distributor instead of treating all supply-chain roles alike.

Deepak Shanti Lal Parekh v. State of Bihar

Summary: The Patna High Court examined prosecution of a GSK non-executive director arising from third-party manufacture, marketing-name labelling and alleged misbranding.

Outcome / action: The application was allowed and cognizance was quashed against the non-executive director because the complaint alleged no specific role and the Magistrate had mechanically used a prepared printed format.

Practical impact: Marketing identity on a label does not itself establish a non-executive director’s criminal responsibility; complaints and process orders require person-specific facts.